Behavioral Therapy Of Obstetric Sphincter Tears (BOOST)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01166399 |
Recruitment Status :
Completed
First Posted : July 21, 2010
Last Update Posted : September 10, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Fecal Incontinence |
The primary aim of the "BOOST Cohort Study" is to determine the incidence of FI symptoms at 6 and 12 weeks postpartum in primiparous women sustaining an OASI.
Secondary aims of the cohort study are:
- To determine the incidence rates of FI symptoms at 24 weeks post delivery in primiparous women sustaining an OASI
- To examine the relationship between the modified WHO sphincter tear classification types and FI symptoms
- To examine predictors (socio-demographic, physical and clinical) associated with WHO sphincter tear classifications (3a, 3b and 4) and predictors associated with FI symptoms
- To evaluate the incidence of fecal urgency and flatal incontinence at 24 weeks postpartum in primiparous women sustaining an OASI.
Study Type : | Observational |
Actual Enrollment : | 362 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | BOOST: Behavioral Therapy of Obstetric Sphincter Tears: A Cohort Study |
Study Start Date : | July 2010 |
Actual Primary Completion Date : | June 2011 |
Actual Study Completion Date : | October 2012 |

Group/Cohort |
---|
Primiparous women with an obstetric anal sphincter tear
Subjects in this trial will be primiparous women who underwent anal sphincter repair at the time of a singleton vaginal delivery. Sphincter tears will be clinically characterized at the time of delivery as <50% tear through the anal sphincter (modified WHO 3a), >50% (modified WHO 3b), or complete tear through the anal sphincter (4th degree). Subjects in this study will not have receive study interventions.
|
- Incidence of FI [ Time Frame: 6 and 12 months postpartum ]The primary aim for this study is to determine the incidence of FI symptoms (based on the FISI)at 6 and 12 weeks postpartum in primiparous women sustaining an OASI.
- Incidence of FI [ Time Frame: 24 weeks postpartum ]A secondary aim for this study is to determine the incidence of FI symptoms (based on the FISI) at 24 weeks postpartum in primiparous women sustaining an OASI.
- Fecal urgency [ Time Frame: 24 weeks postpartum ]Fecal urgency will be assessed at 24 weeks based on the one question from the Modified Manchester questionnaire

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria Assessed by 2 weeks postpartum
- Vaginal delivery >= 28 weeks singleton gestation
- Documented repair to the anal sphincter at delivery
- First vaginal delivery
- Ambulatory
- Able to give informed consent 6 Adult women >= 18 years of age
Inclusion Criteria at 2 weeks postpartum
- Inflammatory bowel disease (e.g., ulcerative colitis or Crohn's disease)
- Pre-pregnancy ano-rectal surgery (e.g., surgery for hemorrhoids, fissures, sphincterotomy)
- Pre-pregnancy FI (defined as the leakage of liquid/solid stool and mucus >= once per month for at least 12 weeks prior to this pregnancy)
- Neurological condition that would predispose to FI (e.g., spinal cord injury, multiple sclerosis)
- Presence of rectovaginal fistula
- Any participation in other pharmacologic or behavioral studies for FI
- Previous pregnancy >=28 weeks delivered vaginally or by Cesarean section

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01166399
United States, Alabama | |
University of Alabama at Birmingham | |
Birmingham, Alabama, United States, 35294 | |
United States, California | |
University of California San Diego | |
La Jolla, California, United States, 92037 | |
United States, Illinois | |
Loyola University | |
Maywood, Illinois, United States, 60153 | |
United States, North Carolina | |
Duke University | |
Durham, North Carolina, United States, 27710 | |
United States, Ohio | |
Cleveland Clinic | |
Cleveland, Ohio, United States, 44195 | |
United States, Pennsylvania | |
University of Pittsburgh | |
Pittsburgh, Pennsylvania, United States, 15260 | |
United States, Texas | |
University of Texas Southwestern | |
Dallas, Texas, United States, 75390 | |
United States, Utah | |
University of Utah | |
Salt Lake City, Utah, United States, 84132 |
Study Chair: | Holly E Richter, PhD, MD | University of Alabama at Birmingham |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | NICHD Pelvic Floor Disorders Network |
ClinicalTrials.gov Identifier: | NCT01166399 |
Other Study ID Numbers: |
20P01 |
First Posted: | July 21, 2010 Key Record Dates |
Last Update Posted: | September 10, 2020 |
Last Verified: | September 2020 |
Fecal Incontinence, bowel incontinence, pelvic floor disorder |
Fecal Incontinence Rectal Diseases Intestinal Diseases Gastrointestinal Diseases Digestive System Diseases |